Refine Results
  1. "Neuroblastoma Service"
Formats
  1. Journal Article (422)
  2. Meeting Abstract (227)
  3. Conference Paper (12)
  4. Book Section (11)
  5. Correspondence (2)
  6. Editorial (2)
  7. Review (2)
  8. Book Whole (1)
Groups
  1. Neuroblastoma Service (679)
  2. Pediatrics, Department of (679)
  3. GSK Faculty (573)
  4. Center for Hematologic Malignancies (185)
  5. Neuro-Oncology Service (171)
  6. Pediatric Leukemia (153)

More Groups

People
  1. Nai-Kong Cheung (553)
  2. Brian Kushner (244)
  3. Shakeel Modak (195)
  4. Kim Kramer (154)
  5. Michael La Quaglia (93)
  6. Steven Larson (82)

More People

Years
  1. 2020 (46)
  2. 2019 (41)
  3. 2018 (46)
  4. 2017 (39)
  5. 2016 (29)
  6. 2015 (29)

More Years

Publications
  1. Pediatric Blood and Cancer (87)
  2. Journal of Clinical Oncology (78)
  3. Cancer Research (35)
  4. Neuro-Oncology (28)
  5. International Journal of Radiation Oncology, Biology, Physics (25)
  6. Clinical Cancer Research (24)

More Publications

Publishers
  1. Wiley Periodicals, Inc (90)
  2. American Association for Cancer Research (88)
  3. American Society of Clinical Oncology (79)
  4. Elsevier Inc. (47)
  5. Oxford University Press (35)
  6. Nature Publishing Group (29)

More Publishers

Results (679)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: Results of a phase I study
    Journal Article

    Modak, S.; Zanzonico, P.; Grkovski, M.; Slotkin, E. K.; Carrasquillo, J. A.; Lyashchenko, S. K.; Lewis, J. S.; Cheung, I. Y.; Heaton, T.; LaQuaglia, M. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • International, multicenter phase II trial with humanized anti-GD2 monoclonal antibody naxitamab for treatment of refractory/relapsed high-risk neuroblastoma: Efficacy and safety data
    Meeting Abstract

    Mora, J.; Chan, G.; Morgenstern, D.; Nysom, K.; Bear, M.; Dalby, L. W.; Lisby, S.; Kushner, B.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Reactive regional lymphadenopathy associated with neuroblastoma immunotherapy
    Meeting Abstract

    Lentini-Rivera, A.; Kushner, B.; Modak, S.; Price, A.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Surveillance for early detection of neuroblastoma central nervous system relapse
    Meeting Abstract

    Modak, S.; Kushner, B.; Cheung, N. K.; Kramer, K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Updated entrectinib data from a phase 1/2 trial in children and adolescents with recurrent or refractory solid tumors, including primary central nervous system (CNS) tumors
    Meeting Abstract

    Desai, A. V.; Robinson, G. W.; Basu, E. M.; Foster, J.; Gauvain, K.; Sabnis, A. J.; Macy, M. E.; Maese, L.; Yoon, J.; Cash, T.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Telemedicine blood pressure monitoring after anti-GD2 monoclonal antibody immunotherapy during the COVID-19 pandemic
    Meeting Abstract

    Glincher, R.; Cheung, N. K.; Kasper, C.; Scoppetuolo, L. A.; Modak, S.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Favorable toxicity profile of bivalent GD2/GD3 neuroblastoma vaccine
    Meeting Abstract

    Modak, S.; Cheung, N. K.; Basu, E.; Roberts, S.; Kushner, B.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save